Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 4/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6786610 | 1.00 | HSD17B2 (0.40) | HSD17B2EPHX1ACP3PTGS2GAA | |
| SCHEMBL6798684 | 1.00 | HSD17B2 (0.40) | HSD17B2EPHX1ACP3PTGS2GAA | |
| SCHEMBL10620249 | 0.90 | ALDH1A1 (0.41) | HSD17B2EPHX1GAAALDH1A1KDM4C | |
| SCHEMBL6791191 | 0.88 | MMP2 (0.35) | HSD17B2GAAFFAR1ALDH1A1 | |
| SCHEMBL6841040 | 0.87 | MEN1 (0.35) | HSD17B2EPHX1GAAALDH1A1KDM4C | |
| SCHEMBL6800602 | 0.86 | TDP1 (0.45) | HSD17B2EPHX1GAAFFAR1ALDH1A1 | |
| SCHEMBL6792155 | 0.84 | SRD5A2 (0.43) | — | |
| SCHEMBL6793693 | 0.82 | LMNA (0.42) | HSD17B2GAAFFAR1ALDH1A1 | |
| SCHEMBL6703699 | 0.81 | BACE1 (0.32) | — | |
| SCHEMBL6842484 | 0.80 | TDP2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040110809-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370538-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074752-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110809-A1 | Metalloproteinase inhibitors | MMP9, MMP2, MMP3 | HSD17B2 437/4885EPHX1 474/4885ACP3 270/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | HSD17B2 82/4885EPHX1 650/4885ACP3 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.